Johnson & Johnson (JNJ)
NYSE: JNJ · IEX Real-Time Price · USD
146.14
-0.68 (-0.46%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Johnson & Johnson Revenue
In the year 2023, Johnson & Johnson had annual revenue of $85.16B with 6.46% growth. Revenue in the quarter ending December 31, 2023 was $13.53B with 7.84% year-over-year growth.
Revenue (ttm)
$85.16B
Revenue Growth
+6.46%
P/S Ratio
4.14
Revenue / Employee
$645,633
Employees
131,900
Market Cap
352.17B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
Dec 30, 2018 | 81.58B | 5.13B | 6.71% |
Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
Dec 28, 2014 | 74.33B | 3.02B | 4.23% |
Dec 29, 2013 | 71.31B | 4.09B | 6.08% |
Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
Jan 2, 2005 | 47.35B | 5.49B | 13.10% |
Dec 28, 2003 | 41.86B | 5.56B | 15.33% |
Dec 29, 2002 | 36.30B | 3.98B | 12.32% |
Dec 30, 2001 | 32.32B | 3.15B | 10.78% |
Dec 31, 2000 | 29.17B | 1.17B | 4.16% |
Dec 30, 1999 | 28.01B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
Eli Lilly | 34.12B |
JNJ News
- 3 days ago - PBIRx Growth Fueled by Johnson & Johnson ERISA Lawsuit - Business Wire
- 4 days ago - Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) - Business Wire
- 6 days ago - Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit - Forbes
- 7 days ago - Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson & Johnson, Kenvue, Inc. - Business Wire
- 8 days ago - WHO says wider alert on contaminated J&J cough syrup 'likely' - Reuters
- 8 days ago - What's Next For Johnson & Johnson Stock After Beating Q1 Earnings? - Forbes
- 8 days ago - J&J wins trial over Florida woman who claimed its baby powder caused her cancer - Reuters
- 11 days ago - Johnson & Johnson Amplifies MedTech Profile in Q1 Earnings - PYMNTS